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An acute phase protein ready to go
therapeutic for sepsis
Soﬁe Vandevyver1,2, Lien Dejager1,2, Roosmarijn E Vandenbroucke1,2 & Claude Libert1,2,*
The so-called Acute Phase Response(APR) begins between 12 and 48 hafter the initiation of inflammation.
This conserved response mainly involves
the production of a set of Acute Phase Pro-
teins (APPs) and the downregulation of
other proteins (negative APPs) by hepato-
cytes. Although the precise identity of the
APPs may differ between species, some
APPs are common in all mammals. The APR
is regulated by two major players, glucocor-
ticoids and Interleukin-6 (IL-6). Indeed, most
APP coding genes contain glucocorticoid
receptor responsive (GRE) elements as well
as nuclear factor for IL-6 expression
(NF-IL6) responsive elements (Cray et al,
2009). Also, other family members of IL-6,
for example IL-11, can induce the APR. APPs
are curious in several ways. First, their pro-
duction is remarkably slow. Second, they
are very diverse, and except for a few, their
biological activities are poorly understood.
And third, the function of the APR remains
unclear. Conserved APPs include C-reactive
protein (CRP), alpha-1-acid glycoprotein,
alpha-1-antitrypsin, serum amyloid A, serum
amyloid P, and alpha-2-macroglobulin
(A2MG). Some of these proteins are hardly
detectable in healthy mammals but are
induced 10–1000-fold during inflammation.
Because many of these APPs are heavily gly-
cosylated (by liver enzymes that also behave
like APPs), they are very stable. That is why
some APPs are ideal biomarkers of inflam-
mation, of which CRP is a typical and well-
known example (Pepys & Hirschfield, 2003).
The slow production of APPs and the
known biological activities of some of them
indicate that they form a negative feedback
loop involved in containing pathogens and
limiting the inflammatory cascade. For
example, alpha-1-acid glycoprotein has
strong anti-inflammatory activities only at
high concentrations (thus with poor specific-
ity), and its mechanism of action is unknown
but could be based on inhibition of white
blood cell over-activation (Libert et al,
1994). Other APPs have more defined biolog-
ical activities but they have to be given in
high concentrations to have anti-inflamma-
tory effects. Alpha-1-antitrypsin, the major
neutrophil elastase inhibitor is one of them
(Libert et al, 1996).
......................................................
“… some APPs are ideal bio-
markers of inflammation”
......................................................
Sepsis is a form of systemic inflammatory
response syndrome (SIRS) caused by an
overwhelming reaction to infection, usually
by bacteria. Recent studies estimate that 19
million people are affected by sepsis yearly,
but the true number may be much higher
(Angus & van der Poll, 2013). Since sepsis
causes about 30% mortality, novel therapeu-
tic interventions are urgently needed. The
recent withdrawal of activated protein C
(Xigris, Eli Lilly) from the market and the
discontinuation of a new clinical trial with
an anti-TNF antibody illustrate the difficul-
ties for finding new effective therapeutics.
Basically, sepsis displays typical inflamma-
tory features along with activation of clot-
ting, but also fibrinolysis and immune
suppression, and many mechanisms have
been suggested. Nevertheless, it is clear that
an optimal host response requires that neu-
trophils interact with blood endothelial cells
and travel to the infection site to contain the
pathogens.
In this issue, Dalli et al (2013) report that
a well-known APP, A2MG (Rehman et al,
2013), is an essential player in the host
response to sepsis and has therapeutic poten-
tial. A2MG is a huge glycoprotein of about
750 kDa with 4 identical subunits and anti-
protease activities towards all major classes
of proteases, including bacterial ones. A2MG
also binds many cytokines, such as TNF,
IL-6, IL-1b and a receptor called low-density
lipoprotein receptor-related protein-1
(LRP-1), which leads to production of very
important molecules such as platelet activat-
ing factor and other bioactive lipids.
Anti-inflammatory activities of A2MG have
been known for a long time, for example
from work with A2MG-knockout mice, and
even in models of systemic inflammation
(Hochepied et al, 2002).
The study of Dalli et al, however, takes
the knowledge on A2MG a step further. The
authors found that the plasma of sepsis
patients contains lipid microparticles enriched
in A2MG, presumably produced by neutro-
phils (Fig 1). Interestingly, surviving sepsis
patients have more such A2MG enriched mi-
croparticles than non-surviving patients, sug-
gesting that they are involved in protective
pathways, and that they have a diagnostic
value. Administration of such particles (either
purified or prepared in the lab) to mice led to
significant protection in the golden model of
mouse sepsis research, the cecal ligation and
puncture model (CLP), a surgical model lead-
ing to a septic, lethal peritonitis (Dejager et al,
2011). The authors describe reduced inflam-
mation, better anti-bacterial responses, less
hypothermia, and less mortality in the A2MG
microparticles-treated mice compared to con-
trol. They report that in vivo knockdown of
the A2MG receptor LRP-1 reduces the protec-
tive effects of A2MG. Although one can argue
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that this knockdown study might not be spe-
cific or strong or ubiquitous enough and that
it should be corroborated by knockout tech-
niques, the data strongly suggest that the
effects of A2MG are transmitted by this recep-
tor. In fact, the authors found evidence that
microparticles-derived A2MG is captured on
the cell membrane of endothelial cells, where
it can bind to LRP-1 on neutrophils, which
enhances the adhesion, chemotaxis and anti-
bacterial effects of these cells. It is noteworthy
that in sepsis neutrophils often fail to move to
the infectious site because their chemotaxis is
reduced by declining expression of CXCR2, an
essential chemotaxis receptor, but A2MG
prevented this decline. Finally, in sepsis, a
pro-inflammatory signature is often accompa-
nied by immune-suppressive features. Many
of the failed clinical interventions addressed
inflammatory mediators exclusively, but
reversing the immune-suppressive status, e.g.
using interferon-gamma (IFNc), is emerging
as another necessary intervention. Microparti-
cles containing A2MG not only reduced
inflammation, but also increased the produc-
tion of IFNc locally and systemically.
......................................................
“… a well-known APP, A2MG,
is an essential player in the
host response to sepsis and has
therapeutic potential.”
......................................................
In summary, it is clear that microparticles-
associated A2MG have powerful activities
against sepsis and that the approach of the
authors might prove to be an interesting new
strategy for treatment of patients. The paper
also confirms the recent insights that suggest
that secretion of microparticles is a fast, power-
ful and efficient way for cell-to-cell communica-
tion in times of stress (El Andaloussi et al,
2013). Several questions remain unanswered
however and deserve further attention. The
authors suggest several protectivemechanisms,
such as listed in Fig 1, and one wonders which
one is the most important or dominant. Also,
since A2MG is a well-known APP, could the
microparticles be also produced by hepatocytes
as well as by neutrophils? The authors showed
that microparticles associated A2MG are supe-
rior in protecting against sepsis than free, solu-
ble A2MG, and so it would be interesting to
know whether pharmacokinetics, different
binding to LRP-1, or alternative mechanisms
are responsible for this finding. Since A2MG
is such a huge protein, a screen for other,
smaller ligands of LRP-1 with similar
activities may lead to even better therapeu-
tics. Finally, one ponders whether A2MG also
has therapeutic potential in other types of
systemic inflammation, i.e. in severe trauma,
burns, bleeding or ischemia/reperfusion.
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Figure 1. A much-simplified scheme of
essential features during bacteria-induced
sepsis. In sepsis, several complex systems are
activated, such as the coagulation, fibrinolysis and
complement systems, as well as inflammation and
endothelial dysfunction. Multiple organ failure
(MOF) is the result and death often the end point.
Several feedback rescue systems are also activated.
Inflammation and the activation of the
hypothalamic-pituitary-adrenal axis (HPA) will
activate the acute phase response (APR), leading to
production of APPs such as A2MG. Dalli et al show
that neutrophils (PMN) are activated to move to
the infectious burden but also to produce
microparticles, which may also contain A2MG
(Dalli et al, 2013). The question mark means that it
is uncertain whether the liver produces A2MG in
microvesicles, as neutrophils do. A2MG is
concentrated on the surface of endothelial cells,
bind to LRP-1 on PMNs and stimulate them to help
protecting against sepsis.
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